Drug intelligence / Profile preview

recombinant neorudin

Development stage: Unknown
Lead developer: Fuwai Hospital
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Recombinant neorudin is a direct thrombin inhibitor (DTI) developed by Fuwai Hospital of the Chinese Academy of Medical Sciences. It is a recombinant protein produced in yeast, designed as an anticoagulant for the treatment of non-ST-segment elevation acute coronary syndrome (NSTE-ACS). The drug functions by binding directly to thrombin, thereby blocking its enzymatic activity in the coagulation cascade and preventing fibrin formation. It is currently being investigated in Phase 1 clinical trials in China to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in adult patients with NSTE-ACS who are not candidates for emergency interventional therapy.

Other names: recombinant neorudin (yeast)

Targets

F2 (Thrombin)

Beyond the preview

Go deeper on recombinant neorudin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant neorudin.

Explore the full profile